Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a first-in-human clinical trial evaluating GB-5267, an autologous IL‑18–armoured CAR T-cell therapy. The therapy is designed to overcome key barriers that have limited the success of cellular therapies in solid tumours. … Read More
Kevan Shokat has been named the 2026 Stephenson Global Prize Laureate, receiving $1 million for his pioneering contributions to pancreatic cancer research. His discoveries helped transform decades of scientific thinking about KRAS, one of cancer’s most important and historically difficult-to-target drivers, and usher in a new generation… Read More
Novartis has revealed plans to pause development of Lifonebart (VHB937), an experimental monoclonal antibody drug targeting the TREM2 protein to treat neurodegenerative diseases. The news comes just days after the company announced its Phase III trial of antibody oligonucleotide conjugate (AOC) del-desiran had failed. VHB937… Read More
US researchers have filed a class action lawsuit challenging the National Institutes of Health’s (NIH) policy of blocking grants to censor views it disagrees with, on everything from DEI to gender identity to climate change. The plaintiffs are represented by the American Civil Liberties Union, the ACLU… Read More
Johnson & Johnson has announced final overall survival (OS) results from the Phase III PAPILLON study of first-line intravenous (IV) Rybrevant (amivantamab). The fully-human EGFR-MET bispecific antibody was assessed with carboplatin-pemetrexed chemotherapy, versus chemotherapy alone, in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth… Read More
Novartis and Bristol Myers Squibb (BMS) have both paused clinical trials of CAR-T cell therapies for lupus and other autoimmune diseases due to concerning safety findings. Novartis has placed holds on trials of rapcabtagene autoleucel (rap-cel), stopping screening, randomisation, and treatment administration in trials in lupus, myasthenia… Read More
Eli Lilly has announced plans to acquire Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases. Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions. The… Read More
African biopharmaceutical company Minapharm Group will receive up to $16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate. The investment is part of efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on… Read More
Researchers have identified inflammatory cytokine interleukin-26 (IL-26) as a factor that acts on cancer cells and induces epigenetic reprogramming, promoting immune evasion. While cancer cells acquire malignant traits through epigenetic remodelling, it remains unclear how immune-derived inflammatory factors regulate the epigenetics of colorectal cancer cells. … Read More
The world-first trial of a fridge-free tetanus-diphtheria vaccine has produced encouraging results that could improve access worldwide to crucial treatments. Around half of vaccines are wasted globally each year, according to the World Health Organization, because of temperature changes during storage and transport. Fridge-free vaccines… Read More
Following Health Canada’s authorisation, the first participants have been vaccinated in Moderna’s Phase I clinical study evaluating mRNA-1469, an mRNA vaccine to prevent Bundibugyo ebolavirus (BDBV). “Vaccinating the first participants with mRNA-1469 marks an important milestone in advancing a vaccine candidate against Bundibugyo ebolavirus, for which no… Read More
Norstella has announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies. The P3i is the first benchmark to follow drug performance across the entire development and commercialisation lifecycle. Read More
Chris McDonald has been appointed the UK’s new science minister following the resignation of Patrick Vallance. McDonald, who became a Minister of State at the newly formed Department for Business, Innovation, Science and Trade (Dbist) on 21 July, also took up a role at the Department of Health and Social… Read More
Eli Lilly has announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase III trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist. In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some… Read More
As the world celebrates International Moon Day (20 July), Switzerland is championing the opportunities space exploration opens for life sciences. Leading international players including Starlab Space and Axiom Space have selected Switzerland as their European hub for the next generation of commercial orbital laboratories, supporting R&D in… Read More
Cancer Research UK is leading a group of partners launching a global Phase II trial into rare adrenal gland cancer. Biotechnology company Cytovation and the Norwegian Cancer Society (NCS) have joined forces with Cancer Research UK for the trial of people with advanced adrenocortical carcinoma (ACC), a rare and… Read More
